| Yesterday |
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< UMGNF Universal Music Group - $20.34 /
+0.1275 (+0.63%) - 01/31/23
- Block's TIDAL, Universal Music Group partner to develop new streaming model
- 03/16/23
- TEN, Ltd. falls -13.2%
- 12/19/22
- TEN, Ltd. releases its inaugural 2021 ESG report
- 05/30/23
- Tingo Group's DMCC commences delivery of significant pipeline of export orders
- 05/22/23
- Tingo Group set to join Russell 3000 Index
- 04/26/23
- Tingo Mobile signs exclusive agreement with PCX, AFAN
- 04/13/23
- Tingo Group regains compliance with Nasdaq minimum bid price rule
- $237.07 /
+3.805 (+1.63%) - 05/26/23
- Funky Buddha Brewery founders to reacquire company from Constellation Brands
- 04/06/23
- Constellation Brands: We're excited by the resiliency of our brands
- 04/06/23
- Constellation Brands CEO says excited about Beer Business innovations
- 04/06/23
- Constellation Brands raises quarterly dividend 11% to 89c per share
- $57.64 /
-6.835 (-10.60%) - 05/30/23
- Skyline Champion falls -9.7%
- 05/30/23
- Skyline Champion falls -9.3%
- 05/30/23
- Skyline Champion falls -11.8%
- 05/22/23
- Boston Beer names Phil Hodges as Chief Supply Chain Officer
- 04/17/23
- BoROSE Lifescience launces TeaPot in the Quebec market
- 04/17/23
- RISE Dispensaries opens RISE Grove City in Pennsylvania
- 03/16/23
- Del Taco, Samuel Adams Boston Lager enter collaboration
- 05/09/23
- State Department approves Oshkosh FMS sale to Slovakia for JLTVs
- 03/06/23
- Oshkosh Defense files bid protest on recent JLTV award decision
- 02/10/23
- Oshkosh falls -12.1%
- $401.14 /
+11.79 (+3.03%) - 05/29/23
- Fly Intel: Top five weekend stock stories
- 05/29/23
- WPP, Nvidia partner to build AI-enabled content engine for digital advertising
- 05/29/23
- Nvidia collaborates with SoftBank to power next-gen data centers
- 05/29/23
- Nvidia launches accelerated ethernet platform for hyperscale Generative AI
- 05/16/23
- Bunge, Nutrien enter strategic alliance to support U.S. farmers
- 05/11/23
- TRC terminates tender offer for Nutrien
- 05/10/23
- Nutrien cuts FY23 adjusted EBITDA to $6.5B-$8.0B from $8.4B-$10.0B
- 04/13/23
- Rogers Corporation announces Michael Web as chief administrative officer
- $393.11 /
+14.14 (+3.73%) - 05/23/23
- Netflix sending email to members sharing outside U.S. households starting today
- 05/23/23
- Netflix appoints Arnold Schwarzenegger as 'chief action officer'
- 05/02/23
- Writers Guild of America goes on strike after studio talks fail
- 04/23/23
- Fly Intel: Top five weekend stock stories
- 05/30/23
- MagnaChip plans to separate display and power businesses into separate entities
- 05/01/23
- MagnaChip announces CFO Shin Young Park went on maternity leave
- 03/21/23
- MagnaChip begins mass production of MOSFET1
- 02/17/23
- MagnaChip falls -9.3%
- 05/09/23
- MediWound announces $10M award from BARDA
- 04/26/23
- MediWound to present Phase 2 EscharEx data at SAWC Spring 2023
- 03/16/23
- MediWound appoints Hani Luxenburg as CFO
- 03/06/23
- MediWound appoints Barry Wolfenson as EVP, strategy and corporate development
- 04/30/23
- Fly Intel: Top five weekend stock stories
- 05/25/23
- Legend: Type II variation application submitted to EMA for CARVYKTI
- 05/25/23
- Bristol-Myers granted FDA Fast Track Designation for 3 milvexian indications
- 05/12/23
- Protagonist and Janssen report data from preclinical studies of JNJ-2113
- 05/11/23
- Johnson & Johnson reports 61.91% increase in ownership of Nano-X Imaging
- 05/30/23
- JBT Corporation to sell its AeroTech business to Oshkosh for $800M
IOVA Iovance Biotherapeutics - 05/26/23
- Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel
- 03/24/23
- Iovance Biotherapeutics completes BLA submission for lifileucel
- 03/10/23
- Iovance says it does not hold deposits, securities at Silicon Valley Bank
- 01/23/23
- Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M
- 05/17/23
- Remark Holdings announces partnership with WaitTime
- 05/10/23
- Intel, BCG announce collaboration
- 04/24/23
- Intel 'the main loser' of Sapphire Rapids' lower demand, says Ming-Chi Kuo
- 04/18/23
- EU takes on US and Asia with EUR 43B chip subsidy plan
- 05/25/23
- Icahn's Teno says activism 'alive and well' after Illumina elects him to board
- 05/25/23
- Illumina confirms Icahn Capital's Andrew Teno elected to board
- 05/25/23
- Icahn Enterprises sinks 21% to $18.80 after Ackman comments on Twitter
- 05/25/23
- Icahn Enterprises 'reminds me somewhat of Archegos,' Ackman says
- 05/08/23
- Hims & Hers up 6% after Q1 earnings, FY23 guidance raise
- 05/08/23
- Hims & Hers reports end-Q1 subscribers up 87% to 1.2M
- 02/28/23
- Hims & Hers rises 20.7%
- 02/28/23
- Hims & Hers rises 11.3%
- 05/25/23
- Cboe Global Markets joins Goldman Sachs, Digital Assets to launch Canton Network
- 05/17/23
- ECB fines Goldman EUR 6.3M for misreporting capital needs
- 05/16/23
- National Western Life to explore strategic alternatives
- 05/25/23
- Ford EV customers to gain access to 12,000 Tesla superchargers
- 05/25/23
- Ford, Tesla CEOs to host Twitter Spaces chat on accelerating EV adoption
- 05/22/23
- SQM announces long-term lithium supply agreement with Ford
- 05/22/23
- Ford sees Ford Blue EBIT margin in low double digits by 2026
- 05/30/23
- Equitrans Midstream rises 34.2%
- 05/30/23
- Equitrans Midstream rises 40.4%
- 05/30/23
- Equitrans Midstream rises 44.7%
- 05/18/23
- Elbit Systems awarded $305M Foreign Military Sales contract
- 05/09/23
- Elbit Systems awarded $71M contract by UK Ministry of Defence
- 04/27/23
- Elbit Systems signs $100M follow-on contract
- 04/18/23
- Elbit Systems awarded $102M contract by international customer
- 05/15/23
- Third Point buys Alibaba, cuts AIG in Q1
- 05/15/23
- Trian Fund buys GE Healthcare, exits Sysco in Q1
- 05/14/23
- Fly Intel: Top five weekend stock stories
- 05/19/23
- CureVac granted motion to transfer U.S. litigation with Pfizer, BioNTech
- 05/08/23
- CureVac doses first patient in Phase 1/2 study of influenza vaccine candidates
- 04/25/23
- CureVac sees cash reach to mid-2025
- 02/01/23
- CureVac appoints Myriam Mendila as CDO
- 05/30/23
- SEC settles with former Coinbase manager and his brother over insider trading
- 05/26/23
- Coinbase exec Brock sells 14,207 class A shares
- 05/22/23
- Coinbase launching 'Crypto: Moving America Forward' ad campaign
- 05/15/23
- Coinbase says aware of issues trading on Coinbase.com
- 05/11/23
- FDIC proposes rule for special assessment on big banks for cost recovery
- 04/20/23
- Comerica sees 2023 average loans up 8%-9%, NII up 6%-7% vs. 2022
- 04/20/23
- Comerica sees Q2 average loans up 3%, with NII down 11%-13%
- 03/27/23
- Comerica rises 8.0%
- 04/04/23
- ChargePoint enters international agreement with ALD Automotive
- 03/03/23
- ChargePoint falls -7.9%
- 03/03/23
- ChargePoint falls -9.2%
- 02/23/23
- Fisker names ChargePoint as North America partner for EV charging stations
- 05/23/23
- Broadcom up 2% after Apple announces 'multibillion-dollar' supply deal
- 05/23/23
- Broadcom reports two separate multi-year statements of work with Apple
- 05/23/23
- Apple reports 'multibillion-dollar' deal with Broadcom for U.S.-made components
- 05/22/23
- United Airlines to support Live Activities for iPhone
- $401.14 /
+11.79 (+3.03%) - 06:47 Today BofA
- Nvidia price target raised to $500 from $450 at BofA
- 06:01 Today Citi
- Citi tells investors to 'stay long' Nvidia shares
- 05/30/23 Goldman Sachs
- nVent Electric price target raised to $58 from $55 at Goldman Sachs
- 05/26/23 TD Cowen
- Marvell price target raised to $65 from $50 at TD Cowen
- 05/30/23 BMO Capital
- Broadcom price target raised to $890 from $750 at BMO Capital
- 05/30/23 KeyBanc
- Broadcom price target raised to $820 from $720 at KeyBanc
- 05/23/23 BofA
- Broadcom price target raised to $800 from $725 at BofA
- 05/22/23 Loop Capital
- Loop downgrades Apple on 'material downside risk' to guidance
- $393.11 /
+14.14 (+3.73%) - 05/30/23 Jefferies
- Netflix price target raised to $440 from $405 at Jefferies
- 05/24/23 Wedbush
- Wedbush remains bullish as Netflix rolls out latest password-sharing crackdown
- 05/24/23 Oppenheimer
- Netflix price target raised to $450 from $415 at Oppenheimer
- 05/19/23 BofA
- BofA survey suggests 'strong growth opportunity ahead' for Netflix
- 04/26/23 Baird
- Baird bumps JBT Corporation price target to $128 after Q1 beat
- 11/02/22 BMO Capital
- JBT Corporation price target lowered to $120 from $135 at BMO Capital
- 10/28/22 Baird
- JBT Corporation price target lowered to $110 from $117 at Baird
- 10/27/22 Baird
- JBT Corporation price target lowered to $110 from $117 at Baird
- 05/09/23 Evercore ISI
- Oshkosh price target lowered to $82 from $89 at Evercore ISI
- 05/01/23 DA Davidson
- Oshkosh price target lowered to $86 from $95 at DA Davidson
- 04/28/23 Stifel
- Oshkosh price target lowered to $101 from $109 at Stifel
- 04/28/23 Credit Suisse
- Oshkosh price target lowered to $96 from $113 at Credit Suisse
- 05/30/23 Roth MKM
- Ford access to Tesla charger network positive for entire space, says Roth MKM
- 05/30/23 Jefferies
- Ford upgraded to Buy from Hold at Jefferies
- 05/25/23 Daiwa
- Ford upgraded to Neutral from Underperform at Daiwa
- 05/17/23 Deutsche Bank
- Deutsche says Ford event may clear way for investor caution
- 05/30/23 BofA
- BofA upgrades ChargePoint to Buy with shares at all-time lows
- 05/30/23 BofA
- ChargePoint upgraded to Buy from Neutral at BofA
- 05/08/23 B. Riley
- ChargePoint price target lowered to $12 from $18 at B. Riley
- 05/02/23 Guggenheim
- ChargePoint initiated with a Neutral at Guggenheim
- 05/30/23 Atlantic Equities
- Coinbase upgraded to Overweight from Neutral at Atlantic Equities
- 05/15/23 Berenberg
- Coinbase initiated with a Hold at Berenberg
- 05/10/23 BofA
- Coinbase price target raised to $47 from $45 at BofA
- 05/08/23 Daiwa
- Coinbase upgraded to Buy from Hold at Daiwa
- $237.07 /
+3.805 (+1.63%) - 05/30/23 Goldman Sachs
- Concerns over Constellation Brands' Modelo overblown, says Goldman Sachs
- 05/30/23 Roth MKM
- Constellation Brands upgraded to Buy from Neutral at Roth MKM
- 05/08/23 Gordon Haskett
- Barclays 13F shows 'interesting' Constellation Brands buy, says Gordon Haskett
- 04/11/23 Barclays
- Constellation Brands price target lowered to $277 from $279 at Barclays
- 05/30/23 Roth MKM
- Boston Beer upgraded to Buy from Neutral at Roth MKM
- 04/28/23 Deutsche Bank
- Boston Beer price target raised to $297 from $291 at Deutsche Bank
- 04/28/23 TD Cowen
- Boston Beer price target lowered to $350 from $375 at TD Cowen
- 04/28/23 Morgan Stanley
- Boston Beer price target lowered to $260 from $270 at Morgan Stanley
- 05/30/23 RBC Capital
- Kenvue initiated with an Outperform at RBC Capital
- 05/30/23 Citi
- Johnson & Johnson resumed with a Buy at Citi
- 05/30/23 JPMorgan
- JPMorgan starts Kenvue with Overweight on 'resilient growth'
- 05/30/23 Goldman Sachs
- Kenvue initiated with a Neutral at Goldman Sachs
- 05/30/23 UBS
- Kenvue initiated with a Neutral at UBS
- 05/30/23 BofA
- Kenvue initiated with a Buy at BofA
- 05/30/23 Exane BNP Paribas
- Kenvue initiated with a Neutral at Exane BNP Paribas
- 05/12/23 Citi
- State Street, BNY Mellon hurt most from FDIC proposal, says Citi
- 05/05/23 JPMorgan
- Comerica upgraded to Overweight from Neutral at JPMorgan
- 05/03/23 Wolfe Research
- Comerica downgraded to Peer Perform from Outperform at Wolfe Research
- 04/21/23 RBC Capital
- Comerica price target lowered to $62 from $68 at RBC Capital
- 05/25/23 Jefferies
- Nvidia price target raised to $472 from $300 at Jefferies
- 05/23/23 BofA
- AMD price target raised to $120 from $105 at BofA
- 05/03/23 BofA
- BofA downgrades AMD to Neutral in 'range of headwinds'
- 04/28/23 Truist
- Intel price target raised to $32 from $29 at Truist
UMGNF Universal Music Group - $20.34 /
+0.1275 (+0.63%) - 04/28/23 Barclays
- Universal Music Group price target lowered to EUR 26.25 from EUR 26.60 at Barclays
- 04/27/23 Credit Suisse
- Universal Music Group price target raised to EUR 24.30 at Credit Suisse
- 04/06/23 Exane BNP Paribas
- Universal Music downgraded to Underperform from Outperform at Exane
- 03/08/23 Morgan Stanley
- Universal Music Group price target lowered to EUR 33 from EUR 36 at Morgan Stanley
- 05/30/23 Truist
- Disney price target lowered to $105 from $121 at Truist
- 05/25/23 KeyBanc
- Disney price target lowered to $107 from $120 at KeyBanc
- 05/25/23 Citi
- ESPN+ could add $20 to Disney shares, says Citi
- 05/19/23 Macquarie
- Disney downgraded to Neutral from Outperform at Macquarie
- 04/19/23 BMO Capital
- Goldman Sachs price target lowered to $414 from $429 at BMO Capital
- 04/19/23 Morgan Stanley
- Goldman Sachs price target raised to $337 from $329 at Morgan Stanley
- 04/19/23 RBC Capital
- Goldman Sachs price target raised to $375 from $339 at RBC Capital
- 05/30/23 RBC Capital
- Equitrans Midstream upgraded to Outperform from Sector Perform at RBC Capital
- 04/21/23 Raymond James
- Equitrans Midstream initiated with a Market Perform at Raymond James
- 04/10/23 Barclays
- Equitrans Midstream price target lowered to $6 from $8 at Barclays
- 01/31/23 Goldman Sachs
- Equitrans Midstream double downgraded to Sell at Goldman on MVP delay
IOVA Iovance Biotherapeutics - 05/30/23 Wells Fargo
- Iovance upgraded to Overweight at Wells Fargo after lifileucel BLA accepted
- 05/30/23 Wells Fargo
- Iovance Biotherapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- 05/30/23 Stifel
- Iovance Biotherapeutics price target raised to $24 from $21 at Stifel
- 05/29/23 Barclays
- Iovance news 'important clearing event' for shares, says Barclays
- 05/17/23 Taglich Brothers
- Tingo Group price target raised to $11.75 from $6.25 at Taglich Brothers
- 05/30/23 Morgan Stanley
- Mosaic price target lowered to $40 from $45 at Morgan Stanley
- 05/30/23 Morgan Stanley
- Nutrien price target lowered to $70 from $80 at Morgan Stanley
- 05/30/23 Morgan Stanley
- CF Industries price target lowered to $70 from $75 at Morgan Stanley
- 05/19/23 JPMorgan
- Nutrien price target lowered to $78 from $92 at JPMorgan
- 05/30/23 Piper Sandler
- Hims & Hers price target lowered to $11 from $12 at Piper Sandler
- 05/09/23 SVB Securities
- SVB Securities keeps Market Perform on Hims & Hers, raises price target to $11
- 05/09/23 BofA
- Hims & Hers price target raised to $15 from $13.50 at BofA
- 05/09/23 Piper Sandler
- Hims & Hers price target raised to $12 from $11 at Piper Sandler
- $57.64 /
-6.835 (-10.60%) - 02/08/23 Craig-Hallum
- Skyline Champion price target raised to $78 from $65 at Craig-Hallum
- 02/08/23 RBC Capital
- Skyline Champion price target raised to $65 from $54 at RBC Capital
- 12/30/22 Wedbush
- Wedbush favors four homebuilding stocks heading into 2023
- 12/14/22 Barclays
- Skyline Champion downgraded to Equal Weight from Overweight at Barclays
- 04/26/23 JMP Securities
- CureVac price target lowered to $24 from $34 at JMP Securities
- 01/30/23 JMP Securities
- JMP Securities says older-adult update continues to look encouraging for CureVac
- 01/19/23 UBS
- UBS upgrades CureVac after 'major milestone and clearing event'
- 01/19/23 UBS
- CureVac upgraded to Buy from Neutral at UBS
- 01/03/23 H.C. Wainwright
- H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
- 12/30/22 TD Cowen
- MediWound price target raised to $25 from $6 at Cowen
- 12/29/22 Oppenheimer
- MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer
- 12/22/22 Maxim
- MediWound initiated with a Buy at Maxim
- 11/29/22 Jefferies
- TEN, Ltd. price target raised to $26 from $25 at Jefferies
- 11/23/22 Stifel
- TEN, Ltd. price target raised to $19 from $16 at Stifel
- 09/06/22 Jefferies
- TEN, Ltd. upgraded to Buy from Hold at Jefferies
- 07/20/22 Jefferies
- TEN, Ltd. initiated with a Hold at Jefferies
- 05/30/23
- TEN, Ltd. reports Q1 EPS $5.69 vs. (13c) last year
- 03/16/23
- TEN, Ltd. reports Q4 EPS $3.17 vs. ($5.05) last year
- 05/15/23
- Tingo Group reports Q1 EPS 33c vs 7c last year
- 03/31/23
- Tingo Group reports 2022 EPS (36c) vs. (32c) last year
- $237.07 /
+3.805 (+1.63%) - 04/06/23
- Constellation Brands sees 2024 comparable EPS $11.70-$12.00, consensus $11.68
- 04/06/23
- Constellation Brands reports Q4 comparable EPS ex-Canopy $2.15
- 04/06/23
- Constellation Brands reports Q4 comparable EPS $1.98, consensus $1.82
- 04/05/23
- Notable companies reporting before tomorrow's open
- $57.64 /
-6.835 (-10.60%) - 05/30/23
- Skyline Champion reports Q4 EPS $1.00, consensus 93c
- 02/06/23
- Skyline Champion reports Q3 EPS $1.44, consensus 92c
- 04/27/23
- Boston Beer sees FY23 EPS $6.00-$10.00, consensus $7.45
- 04/27/23
- Boston Beer reports Q1 EPS (73c), consensus (31c)
- 02/15/23
- Boston Beer sees FY23 GAAP EPS $6.00-$10.00, consensus $11.02
- 02/15/23
- Boston Beer reports Q4 GAA EPS (93c), consensus 70c
- 04/27/23
- Oshkosh reports Q1 EPS $1.59, consensus $1.02
- 01/31/23
- Oshkosh sees FY23 EPS $5.50, consensus $6.55
- 01/31/23
- Oshkosh reports Q4 EPS $1.60, consensus $1.73
- $401.14 /
+11.79 (+3.03%) - 05/24/23
- Nvidia jumps 15% to $350.53 after Q1 beat, better than expected guidance
- 05/24/23
- Nvidia sees Q2 revenue $11B +/- 2%, consensus 7.15B
- 05/24/23
- Nvidia sees Q2 revenue $11B, +/- 2%, consensus $7.15B
- 05/24/23
- Nvidia reports Q1 EPS $1.09, consensus 92c
- 05/10/23
- Nutrien cuts FY23 EPS view to $5.50-$7.50 from $8.45-$10.65, consensus $8.63
- 05/10/23
- Nutrien reports Q1 EPS $1.11, consensus $1.48
- 02/15/23
- Nutrien sees FY23 adjusted EPS $8.45-$10.65, consensus $11.49
- 02/15/23
- Nutrien reports Q4 adjusted EPS $2.02, consensus $2.62
- $393.11 /
+14.14 (+3.73%) - 04/18/23
- Netflix sees Q2 EPS $2.84, consensus $3.05
- 04/18/23
- Netflix reports Q1 EPS $2.88, consensus $2.86
- 04/18/23
- Notable companies reporting after market close
- 01/19/23
- Netflix sees Q1 EPS $2.82, consensus $2.97
- 05/03/23
- MagnaChip reports Q1 EPS (24c), consensus (27c)
- 02/16/23
- MagnaChip sees Q1 revenue $55M-$59M ,consensus $63.63M
- 02/16/23
- MagnaChip reports Q4 non-GAAP EPS 36c, consensus (20c)
- 05/30/23
- MediWound reports Q1 EPS (44c), consensus (30c)
- 03/16/23
- MediWound reports Q4 EPS ($1.18), consensus (59c)
- 04/18/23
- Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65
- 04/18/23
- Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51
- 04/17/23
- Notable companies reporting before tomorrow's open
- 02/28/23
- Fate Therapeutics reports Q4 EPS (58c), consensus (86c)
- 04/25/23
- JBT Corporation backs FY23 EPS view $5.00-$5.50, consensus $5.34
- 04/25/23
- JBT Corporation sees Q2 adjusted EPS $1.10-$1.25, consensus $1.24
- 04/25/23
- JBT Corporation reports Q1 adjusted EPS 94c, consensus 73c
- 02/21/23
- JBT Corporation sees FY23 adjusted EPS $5.00-$5.50, consensus $5.46
IOVA Iovance Biotherapeutics - 05/09/23
- Iovance Biotherapeutics reports Q1 EPS (50c), consensus (74c)
- 02/28/23
- Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c)
- 04/27/23
- Intel sees Q2 EPS adjusted (4c), consensus 1c
- 04/27/23
- Intel reports Q1 adjusted EPS (4c), consensus (15c)
- 04/27/23
- Notable companies reporting after market close
- 02/22/23
- Intel backs Q1 EPS view (15c), consensus (15c)
- 05/10/23
- Icahn Enterprises reports Q1 EPS (75c) vs. $1.06 last year
- 02/24/23
- Icahn Enterprises reports Q4 EPS (74c) vs. ($1.72) last year
- 05/08/23
- Hims & Hers sees Q2 revenue $200M-$205M, consensus $183.3M
- 05/08/23
- Hims & Hers raises FY23 revenue view to $810M-$830M, consensus $755.28M
- 05/08/23
- Hims & Hers reports Q1 EPS (5c), consensus (7c)
- 02/27/23
- Hims & Hers sees FY23 revenue $735M-$755M, consensus $726.92M
- 04/18/23
- Goldman Sachs reports Q1 EPS $8.79, consensus $8.10
- 01/17/23
- Goldman Sachs reports Q4 EPS $3.32, consensus $5.48
- 05/22/23
- Ford backs FY23 adjusted EBIT view of $9B-$11B
- 05/02/23
- Ford reports Q1 adjusted EPS 63c, consensus 41c
- 05/02/23
- Notable companies reporting after market close
- 05/01/23
- Notable companies reporting before tomorrow's open
- 05/02/23
- Equitrans Midstream reports Q1 adjusted EPS 22c, consensus 15c
- 02/21/23
- Equitrans Midstream sees FY23 adjusted EBITDA $1.06B-$1.14B
- 02/21/23
- Equitrans Midstream sees Q1 adjusted EBITDA $270M-$290M
- 02/21/23
- Equitrans Midstream sees Q1 adjusted EBITDA $270M-$290M
- 05/30/23
- Elbit Systems reports Q1 EPS $1.70 vs. $1.22 last year
- 03/28/23
- Elbit Systems reports Q4 adjusted EPS $1.68 vs. $2.14 last year
- 05/10/23
- Disney reports Q2 EPS ex-items 93c, consensus 93c
- 05/10/23
- Notable companies reporting after market close
- 02/08/23
- Disney reports Q1 EPS ex-items 99c, consensus 78c
- 02/08/23
- Notable companies reporting after market close
- 05/30/23
- CureVac reports Q1 revenue EUR 7.1M vs. EUR 24.4M last year
- 04/25/23
- CureVac reports Q4 revenue EUR 11.7M vs. EUR 41.2M last year
- 05/04/23
- Coinbase reports Q1 subscription and services revenue $362M
- 05/04/23
- Coinbase maintains goal to improve FY23 EBITDA versus FY22
- 05/04/23
- Coinbase reports Q1 EPS (34c) vs ($1.98) last year
- 02/21/23
- Coinbase reports Q4 EPS ($2.46) vs. $3.32 y/y
- 04/20/23
- Comerica reports Q1 EPS $2.39, consensus $2.29
- 04/19/23
- Notable companies reporting before tomorrow's open
- 01/19/23
- Comerica reports Q4 EPS $2.58, consensus $2.55
- 03/03/23
- ChargePoint sees Q1 revenue $122M-$132M, consensus $152.5M
- 03/02/23
- ChargePoint reports Q4 EPS (23c), consensus (17c)
- 12/01/22
- ChargePoint narrows FY23 revenue view to $475M-$485M from $450M-$500M
- 12/01/22
- ChargePoint sees Q4 revenue $160M-$170M, consensus $160.91M
- 05/21/23
- Fly Intel: Top five weekend stock stories
- 05/04/23
- Apple sees Q3 revenue growth 'similar' to Q2, consensus $84.71B
- 05/04/23
- Apple sees Q3 revenue 'similar' to Q2, consensus $84.71B
- 05/04/23
- Apple reports Q2 EPS $1.52, consensus $1.43
|
|
Conference/Events
| ShowHide Related Items >><< - 05/25/23
- Verastem's vutometinib shows 45% response rate in recurrent ovarian cancer
- 04/26/23
- Interim analysis of Verastem's RAMP 201 trial to be presented at ASCO
- 01/24/23
- Verastem reports interim data from Part A of the ongoing RAMP 201 Phase 2 study
VIRX Viracta Therapeutics - 05/02/23
- Viracta Therapeutics CMO Lisa Rojkjaer, M.D to depart
- 01/19/23
- Viracta Therapeutics announces EC orphan drug designation for Nana-val
- 01/08/23
- Viracta announces first clinical response in EBV+ solid tumor setting
- 11/30/22
- Viracta reports Phase 1b/2 trial results for Nana-val in EBV+ tumors
SWTX SpringsWorks Therapeutics - 05/30/23
- SpringsWorks Therapeutics says Phase 2 nirogacestat trial fully enrolled
- 04/17/23
- MapKure, SpringWorks, BeiGene present data from Phase 1a/1b study of BGB-3245
- 02/27/23
- SpringsWorks announces FDA acceptance, priority review of nirogacestat NDA
- 12/27/22
- SpringsWorks Therapeutics completes submission of nirogacestat NDA to FDA
RVMD Revolution Medicines - 12/19/22
- Revolution Medicines announces publication on design, synthesis of RMC-5552
- 12/07/22
- Revolution to regain rights to RMC-4630 following Sanofi deal termination
- 12/07/22
- Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines
- 05/25/23
- Regeneron says updated Linvoseltamab data demonstrates durable responses
- 05/25/23
- Regeneron reports 'positive' data from Fianlimab-Libtayo combo trial
- 05/21/23
- Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results
- 05/18/23
- Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims
ONCT Oncternal Therapeutics - 04/03/23
- Oncternal Therapeutics falls 41% to 46c per share after drug development halt
- 04/03/23
- Oncternal Therapeutics trading resumes
- 04/03/23
- Oncternal Therapeutics to resume trading at 4:30pm ET
- 04/03/23
- Oncternal Therapeutics halts development of zilovertamab, ibrutinib combination
- 05/24/23
- Mirati Therapeutics falls 10% after SAPPHIRE study did not meet primary endpoint
- 05/24/23
- Mirati Therapeutics trading resumes
- 05/24/23
- Mirati Therapeutics says SAPPHIRE study did not meet primary endpoint
- 05/24/23
- Mirati Therapeutics trading halted, news pending
- 05/23/23
- Moderna, BioNTech other Covid vaccine makers jump amid China Covid scare
- 05/19/23
- Moderna reports interim data from Phase 1/2 trial of mRNA-3927
- 05/04/23
- Moderna up 5% after Q1 results beat estimates
- 05/04/23
- Moderna, Novocol Pharma enter long-term fill-finish agreement
- 04/17/23
- Kinnate Biopharma adds two candidates to pipeline, provides cash runway guidance
- 04/17/23
- Kinnate Biopharma announces 'positive' monotherapy dose escalation data
- 02/21/23
- Kinnate Biopharma acquires ownership stake of Kinnjiu Biopharma for $24M
- 02/14/23
- Kinnate Biopharma granted fast track designation for KIN-3248 from FDA
- 04/18/23
- Immuneering down 5% at $11.53 after pricing $30M stock offering
- 04/18/23
- Immuneering announces initial Phase 1 PK, PD, safety data for IMM-1-104
- 03/28/23
- Immuneering appoints Harold Brakewood as CBO
- 03/05/23
- Immuneering presents preclinical data with lead program IMM-1-104
- 05/26/23
- Gilead announces CHMP reccomendation for the use of Veklury
- 05/17/23
- Gilead to present advances across its oncology pipeline at ASCO Annual Meeting
- 05/15/23
- Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead
- 05/15/23
- Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus
- 05/25/23
- Erasca to present HERKULES-3 phase 1b data for ERAS-007 at ASCO
- 05/16/23
- Erasca appoints Davd Chacko as CBO, Nik Chetwyn as COO
- 05/01/23
- Erasca announces U.S. FDA granted FTD to ERAS-801
- 04/25/23
- Erasca announces publication of clinical data on naporafenib
DAWN Day One Biopharmaceuticals - 01/08/23
- Day One announces top line data from pivotal Phase 2 FIREFLY-1 trial
- 03/06/23
- Compugen doses first patient in proof-of-concept study evaluating COM701
- 02/14/23
- Compugen: Rilvegostomig expected to progress into Phase 3 this year
- 12/06/22
- Compugen's COM701 shows durable anti-tumor activity in ovarian cancer
- 12/01/22
- Compugen's COM701 shows preliminary anti-tumor activity in ovarian cancer
- 05/01/23
- Biomea says FDA clearance of IND application to begin Phase I trial of BMF-500
- 04/19/23
- Biomea Fusion to present late breaking data from Phase II trial, COVALENT-111
- 03/28/23
- Biomea Fusion trading resumes
- 03/28/23
- Biomea Fusion trading halted, volatility trading pause
- 05/30/23
- BioLight announces joint cooperation agreement with AstraZeneca's Alexion
- 05/30/23
- Catalyst Pharmaceuticals appoints Thompson to board of directors
- 05/30/23
- Bolt Biotherapeutics and AstraZeneca Rare Disease partner in retinal disease R&D
- 05/26/23
- AstraZeneca announces results from Imfinzi plus Lynparza trial
- 05/03/23
- Agenus up 4% after FDA approves GSK's Arexvy RSV vaccine
- 04/26/23
- Agenus to present Phase 1, Phase 2 trial data at ASCO meeting
- 04/17/23
- Agenus receives Fast Track Designation from FDA for botensilimab, balstilimab
- 03/27/23
- Agenus announces results from cohort in study of botensilimab with balstilimab
- 05/25/23 EF Hutton
- Agenus assumed with a Buy at EF Hutton
- 05/09/23 H.C. Wainwright
- Agenus's progress continues with data presentations, says H.C. Wainwright
- 04/20/23 B. Riley
- B. Riley came away 'encouraged' on Agenus after AACR
- 02/28/23 H.C. Wainwright
- Agenus assumed with a Buy at H.C. Wainwright
- 02/08/23 Jefferies
- Compugen downgraded to Underperform from Hold at Jefferies
- 01/04/23 EF Hutton
- Compugen initiated with a Buy at EF Hutton
- 11/14/22 Oppenheimer
- Compugen price target lowered to $8 from $12 at Oppenheimer
- 08/23/22 Truist
- Compugen price target lowered to $4 from $14 at Truist
DAWN Day One Biopharmaceuticals - 05/01/23 Oppenheimer
- Day One language around NDA submission 'sounded ominous,' says Oppenheimer
- 05/01/23 H.C. Wainwright
- Day One pullback brings attractive entry point, says H.C. Wainwright
- 04/25/23 BofA
- Day One Biopharmaceuticals double downgraded at BofA on regulatory risks
- 04/25/23 BofA
- Day One Biopharmaceuticals downgraded to Underperform from Buy at BofA
- 03/29/23 Mizuho
- Erasca initiated with a Buy at Mizuho
- 02/24/23 Goldman Sachs
- Erasca initiated with a Buy at Goldman Sachs
- 02/03/23 Morgan Stanley
- Erasca upgraded to Overweight from Equal Weight at Morgan Stanley
- 04/19/23 Mizuho
- Immuneering upgraded to Buy from Neutral at Mizuho
- 04/19/23 Morgan Stanley
- Immuneering upgraded to Equal Weight from Underweight at Morgan Stanley
- 04/18/23 Chardan
- Immuneering price target raised to $22 from $18 at Chardan
- 03/29/23 Mizuho
- Immuneering initiated with a Neutral at Mizuho
- 05/18/23 H.C. Wainwright
- Kinnate Biopharma price target lowered to $24 from $25 at H.C. Wainwright
- 04/20/23 H.C. Wainwright
- Kinnate Biopharma price target lowered to $25 from $33 at H.C. Wainwright
- 04/18/23 Stifel
- Kinnate Biopharma price target lowered to $5 from $8 at Stifel
- 04/18/23 Wedbush
- Kinnate Biopharma price target lowered to $14 from $25 at Wedbush
- 05/25/23 Oppenheimer
- Oppenheimer upgrades Mirati to Outperform with Krazati expectations reset
- 05/25/23 Oppenheimer
- Mirati Therapeutics upgraded to Outperform from Perform at Oppenheimer
- 05/25/23 BMO Capital
- Mirati Therapeutics price target lowered to $40 from $50 at BMO Capital
- 05/25/23 Barclays
- Mirati Therapeutics price target lowered to $75 from $90 at Barclays
RVMD Revolution Medicines - 05/09/23 JPMorgan
- Revolution Medicines price target lowered to $35 from $38 at JPMorgan
- 02/28/23 Needham
- Revolution Medicines price target raised to $38 from $32 at Needham
- 02/28/23 Oppenheimer
- Revolution Medicines price target raised to $35 from $30 at Oppenheimer
- 02/28/23 JPMorgan
- Revolution Medicines upgraded to Overweight from Neutral at JPMorgan
VIRX Viracta Therapeutics - 05/10/23 H.C. Wainwright
- Viracta Therapeutics price target lowered to $33 from $35 at H.C. Wainwright
ONCT Oncternal Therapeutics - 04/06/23 Cantor Fitzgerald
- Oncternal downgraded to Neutral from Overweight at Cantor Fitzgerald
- 04/04/23 Maxim
- Oncternal Therapeutics downgraded to Hold from Buy at Maxim
- 04/04/23 Cantor Fitzgerald
- Oncternal Therapeutics price target lowered to $1.30 from $4.00 at Cantor Fitzgerald
- 04/04/23 H.C. Wainwright
- Oncternal Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- 05/25/23 EF Hutton
- Biomea Fusion assumed with a Buy at EF Hutton
- 05/18/23 Citi
- Biomea Fusion price target lowered to $53 from $55 at Citi
- 05/12/23 Barclays
- Biomea Fusion initiated with an Overweight at Barclays
- 04/19/23 H.C. Wainwright
- Biomea Fusion price target lowered to $37 from $44 at H.C. Wainwright
- 05/05/23 Morgan Stanley
- Moderna price target lowered to $153 from $185 at Morgan Stanley
- 04/25/23 Guggenheim
- Moderna initiated with a Neutral at Guggenheim
- 04/13/23 Baird
- Carisma Therapeutics initiated with an Outperform at Baird
- 04/12/23 BofA
- BofA says 'left with more questions than answers' after Moderna Vaccines Day
- 05/19/23 Piper Sandler
- Regeneron Q1 Eylea miss 'not about share, says Piper Sandler
- 05/08/23 Guggenheim
- Regeneron price target lowered to $935 from $960 at Guggenheim
- 05/05/23 Morgan Stanley
- Regeneron price target raised to $927 from $880 at Morgan Stanley
- 05/05/23 SVB Securities
- Regeneron price target lowered to $895 from $976 at SVB Securities
- 05/26/23 Argus
- AstraZeneca price target lowered to $80 from $85 at Argus
- 05/09/23 Berenberg
- AstraZeneca price target raised to 135 GBp from 124 GBp at Berenberg
- 04/28/23 JPMorgan
- AstraZeneca price target raised to 14,000 GBp from 13,500 GBp at JPMorgan
- 04/13/23 Argus
- AstraZeneca price target raised to $85 from $75 at Argus
- 05/16/23 BMO Capital
- Gilead upgraded to Outperform from Market Perform at BMO Capital
- 04/28/23 Piper Sandler
- Gilead assumed with an Overweight at Piper Sandler
- 04/12/23 Morgan Stanley
- Gilead price target raised to $85 from $81 at Morgan Stanley
- 04/05/23 Guggenheim
- InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA
- 05/10/23 H.C. Wainwright
- Verastem price target lowered to $2 from $3 at H.C. Wainwright
- 03/29/23 Mizuho
- Verastem initiated with a Neutral at Mizuho
- 11/07/22 H.C. Wainwright
- Verastem price target lowered to $3 from $5 at H.C. Wainwright
- 10/05/22 BTIG
- Verastem price target lowered to $5 from $8 at BTIG
SWTX SpringsWorks Therapeutics - 04/28/23 Barclays
- SpringsWorks Therapeutics price target lowered to $41 from $55 at Barclays
- 03/07/23 H.C. Wainwright
- SpringsWorks Therapeutics price target raised to $105 from $99 at H.C. Wainwright
- 01/02/23 Barclays
- Barclays views GSK acquisition interest as positive for oncology stocks
- 12/01/22 BofA
- SpringsWorks Therapeutics initiated with a Buy, $45 price target at BofA
- 05/09/23
- Verastem reports Q1 EPS (9c), consensus (8c)
- 03/14/23
- Verastem reports Q4 EPS (8c), consensus (10c)
VIRX Viracta Therapeutics - 05/08/23
- Viracta Therapeutics reports Q1 EPS (32c), consensus (31c)
- 03/13/23
- Viracta Therapeutics reports Q4 EPS (27c), consensus (38c)
SWTX SpringsWorks Therapeutics - 05/03/23
- SpringsWorks Therapeutics reports Q1 EPS ($1.18), consensus ($1.25)
- 02/28/23
- SpringsWorks Therapeutics reports Q4 EPS ($1.19), consensus ($1.22)
RVMD Revolution Medicines - 05/08/23
- Revolution Medicines reports Q1 EPS (72c), consensus (81c)
- 02/27/23
- Revolution Medicines sees FY23 net loss $335M-$365M
- 02/27/23
- Revolution Medicines reports Q4 EPS (63c), consensus (82c)
- 05/04/23
- Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56
- 02/03/23
- Regeneron reports Q4 adjusted EPS $12.56, consensus $10.03
- 02/02/23
- Notable companies reporting before tomorrow's open
ONCT Oncternal Therapeutics - 05/04/23
- Oncternal Therapeutics reports Q1 EPS (20c), consensus (20c)
- 05/09/23
- Mirati Therapeutics reports Q1 EPS ($3.18), consensus ($3.55)
- 02/28/23
- Mirati Therapeutics reports Q4 EPS ($3.51), consensus ($3.55)
- 05/04/23
- Moderna sees Q2 sales $200M-$300M, consensus $982.37M
- 02/23/23
- Moderna reports Q4 EPS $3.61, consensus $4.67
- 02/22/23
- Notable companies reporting before tomorrow's open
- 05/11/23
- Kinnate Biopharma reports Q1 EPS (73c), consensus (73c)
- 05/15/23
- Gilead: Arcus deal may reduce Gilead's FY23 GAAP and non-GAAP EPS by 2c
- 04/27/23
- Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84
- 04/27/23
- Gilead reports Q1 Biktarvy sales up 24% y/y
- 04/27/23
- Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54
- 05/15/23
- Erasca reports Q1 EPS (22c), consensus (31c)
- 03/23/23
- Erasca reports Q4 EPS ($1.06) vs. (26c) last year
DAWN Day One Biopharmaceuticals - 05/01/23
- Day One Biopharmaceuticals reports Q1 EPS (59c), consensus (59c)
- 05/15/23
- Compugen reports Q1 EPS (11c), consensus (12c)
- 03/10/23
- Compugen considers exposure to SVB Financial as immaterial
- 02/27/23
- Compugen reports Q4 EPS (4c), consensus (14c)
- 05/02/23
- Biomea Fusion reports Q1 EPS (98c), consensus (81c)
- 03/28/23
- Biomea Fusion reports Q4 EPS (21c), consensus (81c)
- 04/27/23
- AstraZeneca sees FY23 core EPS up high single to low double-digit percentage
- 04/27/23
- AstraZeneca reports Q1 core EPS $1.92, consensus $1.07
- 02/09/23
- AstraZeneca sees FY23 core EPS up high single to low double-digit percentage
- 02/09/23
- AstraZeneca reports Q4 core EPS $1.38, consensus $1.35
- 05/09/23
- Agenus reports Q1 EPS (22c), consensus (21c)
- 03/14/23
- Agenus reports Q4 EPS (24c), consensus (22c)
|
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< UMGNF Universal Music Group - 01/31/23
- Block's TIDAL, Universal Music Group partner to develop new streaming model
- $200.11 /
+6.975 (+3.61%) - 05/25/23
- Ford EV customers to gain access to 12,000 Tesla superchargers
- 05/25/23
- Ford, Tesla CEOs to host Twitter Spaces chat on accelerating EV adoption
- 05/16/23
- Tesla CEO says we adjust pricing to match demand based on incoming daily data
- 05/16/23
- Tesla CEO says there's some 'good logic' to starting advertising to reach people
- 03/16/23
- TEN, Ltd. falls -13.2%
- 12/19/22
- TEN, Ltd. releases its inaugural 2021 ESG report
- 05/30/23
- Tingo Group's DMCC commences delivery of significant pipeline of export orders
- 05/22/23
- Tingo Group set to join Russell 3000 Index
- 04/26/23
- Tingo Mobile signs exclusive agreement with PCX, AFAN
- 04/13/23
- Tingo Group regains compliance with Nasdaq minimum bid price rule
- $236.71 /
+3.445 (+1.48%) - 05/26/23
- Funky Buddha Brewery founders to reacquire company from Constellation Brands
- 04/06/23
- Constellation Brands: We're excited by the resiliency of our brands
- 04/06/23
- Constellation Brands CEO says excited about Beer Business innovations
- 04/06/23
- Constellation Brands raises quarterly dividend 11% to 89c per share
- 05/10/23
- Sonos drops 18% to $17.29 after cutting 2023 outlook
- 03/07/23
- Sonos to add support for spatial audio on Apple Music
- 05/30/23
- Skyline Champion falls -9.3%
- 05/30/23
- Skyline Champion falls -11.8%
- $334.32 /
+14.66 (+4.59%) - 05/22/23
- Boston Beer names Phil Hodges as Chief Supply Chain Officer
- 04/17/23
- BoROSE Lifescience launces TeaPot in the Quebec market
- 04/17/23
- RISE Dispensaries opens RISE Grove City in Pennsylvania
- 03/16/23
- Del Taco, Samuel Adams Boston Lager enter collaboration
- 05/09/23
- State Department approves Oshkosh FMS sale to Slovakia for JLTVs
- 03/06/23
- Oshkosh Defense files bid protest on recent JLTV award decision
- 02/10/23
- Oshkosh falls -12.1%
- $411.86 /
+22.51 (+5.78%) - 05/29/23
- Fly Intel: Top five weekend stock stories
- 05/29/23
- WPP, Nvidia partner to build AI-enabled content engine for digital advertising
- 05/29/23
- Nvidia collaborates with SoftBank to power next-gen data centers
- 05/29/23
- Nvidia launches accelerated ethernet platform for hyperscale Generative AI
- 05/16/23
- Bunge, Nutrien enter strategic alliance to support U.S. farmers
- 05/11/23
- TRC terminates tender offer for Nutrien
- 05/10/23
- Nutrien cuts FY23 adjusted EBITDA to $6.5B-$8.0B from $8.4B-$10.0B
- 04/13/23
- Rogers Corporation announces Michael Web as chief administrative officer
- 05/23/23
- Netflix sending email to members sharing outside U.S. households starting today
- 05/23/23
- Netflix appoints Arnold Schwarzenegger as 'chief action officer'
- 05/02/23
- Writers Guild of America goes on strike after studio talks fail
- 04/23/23
- Fly Intel: Top five weekend stock stories
- 05/30/23
- MagnaChip plans to separate display and power businesses into separate entities
- 05/01/23
- MagnaChip announces CFO Shin Young Park went on maternity leave
- 03/21/23
- MagnaChip begins mass production of MOSFET1
- 02/17/23
- MagnaChip falls -9.3%
- 05/09/23
- MediWound announces $10M award from BARDA
- 04/26/23
- MediWound to present Phase 2 EscharEx data at SAWC Spring 2023
- 03/16/23
- MediWound appoints Hani Luxenburg as CFO
- 03/06/23
- MediWound appoints Barry Wolfenson as EVP, strategy and corporate development
- 04/30/23
- Fly Intel: Top five weekend stock stories
- 05/25/23
- Legend: Type II variation application submitted to EMA for CARVYKTI
- 05/25/23
- Bristol-Myers granted FDA Fast Track Designation for 3 milvexian indications
- 05/12/23
- Protagonist and Janssen report data from preclinical studies of JNJ-2113
- 05/11/23
- Johnson & Johnson reports 61.91% increase in ownership of Nano-X Imaging
- 05/30/23
- JBT Corporation to sell its AeroTech business to Oshkosh for $800M
IOVA Iovance Biotherapeutics - 05/26/23
- Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel
- 03/24/23
- Iovance Biotherapeutics completes BLA submission for lifileucel
- 03/10/23
- Iovance says it does not hold deposits, securities at Silicon Valley Bank
- 01/23/23
- Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M
- 05/17/23
- Remark Holdings announces partnership with WaitTime
- 05/10/23
- Intel, BCG announce collaboration
- 04/24/23
- Intel 'the main loser' of Sapphire Rapids' lower demand, says Ming-Chi Kuo
- 04/18/23
- EU takes on US and Asia with EUR 43B chip subsidy plan
- 05/08/23
- Hims & Hers up 6% after Q1 earnings, FY23 guidance raise
- 05/08/23
- Hims & Hers reports end-Q1 subscribers up 87% to 1.2M
- 02/28/23
- Hims & Hers rises 20.7%
- 02/28/23
- Hims & Hers rises 11.3%
- 05/29/23
- Nvidia announces DGX GH200 AI supercomputer
- 05/25/23
- Google starts access to new generative AI capacity in Search
- 05/24/23
- Pershing Square: In very early days of AI development
- 05/22/23
- SQM announces long-term lithium supply agreement with Ford
- 05/22/23
- Ford sees Ford Blue EBIT margin in low double digits by 2026
- 05/30/23
- Equitrans Midstream rises 40.4%
- 05/30/23
- Equitrans Midstream rises 44.7%
- $208.83 /
+15.14 (+7.82%) - 05/18/23
- Elbit Systems awarded $305M Foreign Military Sales contract
- 05/09/23
- Elbit Systems awarded $71M contract by UK Ministry of Defence
- 04/27/23
- Elbit Systems signs $100M follow-on contract
- 04/18/23
- Elbit Systems awarded $102M contract by international customer
- 05/15/23
- Third Point buys Alibaba, cuts AIG in Q1
- 05/15/23
- Trian Fund buys GE Healthcare, exits Sysco in Q1
- 05/14/23
- Fly Intel: Top five weekend stock stories
- 05/19/23
- CureVac granted motion to transfer U.S. litigation with Pfizer, BioNTech
- 05/08/23
- CureVac doses first patient in Phase 1/2 study of influenza vaccine candidates
- 04/25/23
- CureVac sees cash reach to mid-2025
- 02/01/23
- CureVac appoints Myriam Mendila as CDO
- 05/26/23
- Coinbase exec Brock sells 14,207 class A shares
- 05/22/23
- Coinbase launching 'Crypto: Moving America Forward' ad campaign
- 05/15/23
- Coinbase says aware of issues trading on Coinbase.com
- 05/11/23
- Coinbase director buys $50M in common stock
- 05/11/23
- FDIC proposes rule for special assessment on big banks for cost recovery
- 04/20/23
- Comerica sees 2023 average loans up 8%-9%, NII up 6%-7% vs. 2022
- 04/20/23
- Comerica sees Q2 average loans up 3%, with NII down 11%-13%
- 03/27/23
- Comerica rises 8.0%
- 04/04/23
- ChargePoint enters international agreement with ALD Automotive
- 03/03/23
- ChargePoint falls -7.9%
- 03/03/23
- ChargePoint falls -9.2%
- 02/23/23
- Fisker names ChargePoint as North America partner for EV charging stations
- $121.28 /
+1.185 (+0.99%) - 05/29/23
- Nvidia GH200 Grace Hopper Superchip enters full production
- 05/25/23
- Dish jumps 20% after WSJ report on mobile plan talks with Amazon
- 05/23/23
- Amazon opens pre-orders for Fire Max 11 tablet
- 05/18/23
- AWS to invest $12.7B into cloud infrastructure in India
- 05/23/23
- Broadcom up 2% after Apple announces 'multibillion-dollar' supply deal
- 05/23/23
- Broadcom reports two separate multi-year statements of work with Apple
- 05/23/23
- Apple reports 'multibillion-dollar' deal with Broadcom for U.S.-made components
- 05/22/23
- United Airlines to support Live Activities for iPhone
- $411.86 /
+22.51 (+5.78%) - 05/26/23 TD Cowen
- Marvell price target raised to $65 from $50 at TD Cowen
- 05/25/23 Morgan Stanley
- Nvidia price target raised to $450 from $304 at Morgan Stanley
- 05/25/23 Craig-Hallum
- Craig-Hallum upgrades Nvidia to Buy, raises price target to $500 from $190
- 05/25/23 Deutsche Bank
- Nvidia price target raised to $390 from $220 at Deutsche Bank
- 05/30/23 BMO Capital
- Broadcom price target raised to $890 from $750 at BMO Capital
- 05/30/23 KeyBanc
- Broadcom price target raised to $820 from $720 at KeyBanc
- 05/23/23 BofA
- Broadcom price target raised to $800 from $725 at BofA
- 05/22/23 Loop Capital
- Loop downgrades Apple on 'material downside risk' to guidance
- 05/24/23 Wedbush
- Wedbush remains bullish as Netflix rolls out latest password-sharing crackdown
- 05/24/23 Oppenheimer
- Netflix price target raised to $450 from $415 at Oppenheimer
- 05/19/23 BofA
- BofA survey suggests 'strong growth opportunity ahead' for Netflix
- 05/18/23 JPMorgan
- JPMorgan 'incrementally positive' on Netflix after management meeting
- 04/26/23 Baird
- Baird bumps JBT Corporation price target to $128 after Q1 beat
- 11/02/22 BMO Capital
- JBT Corporation price target lowered to $120 from $135 at BMO Capital
- 10/28/22 Baird
- JBT Corporation price target lowered to $110 from $117 at Baird
- 10/27/22 Baird
- JBT Corporation price target lowered to $110 from $117 at Baird
- 05/09/23 Evercore ISI
- Oshkosh price target lowered to $82 from $89 at Evercore ISI
- 05/01/23 DA Davidson
- Oshkosh price target lowered to $86 from $95 at DA Davidson
- 04/28/23 Stifel
- Oshkosh price target lowered to $101 from $109 at Stifel
- 04/28/23 Credit Suisse
- Oshkosh price target lowered to $96 from $113 at Credit Suisse
- $200.11 /
+6.975 (+3.61%) - 05/30/23 Roth MKM
- Ford access to Tesla charger network positive for entire space, says Roth MKM
- 05/30/23 Wedbush
- Musk visits China at key point for Tesla with price wars underway, says Wedbush
- 05/30/23 Barclays
- Tesla must address model concentration, says Barclays
- 05/23/23 Oppenheimer
- Shares may move higher near-term as Tesla outperforms peers, says Oppenheimer
- 05/30/23 Jefferies
- Ford upgraded to Buy from Hold at Jefferies
- 05/25/23 Daiwa
- Ford upgraded to Neutral from Underperform at Daiwa
- 05/17/23 Deutsche Bank
- Deutsche says Ford event may clear way for investor caution
- 05/30/23 BofA
- BofA upgrades ChargePoint to Buy with shares at all-time lows
- 05/30/23 BofA
- ChargePoint upgraded to Buy from Neutral at BofA
- 05/08/23 B. Riley
- ChargePoint price target lowered to $12 from $18 at B. Riley
- 05/02/23 Guggenheim
- ChargePoint initiated with a Neutral at Guggenheim
- 05/30/23 Atlantic Equities
- Coinbase upgraded to Overweight from Neutral at Atlantic Equities
- 05/15/23 Berenberg
- Coinbase initiated with a Hold at Berenberg
- 05/10/23 BofA
- Coinbase price target raised to $47 from $45 at BofA
- 05/08/23 Daiwa
- Coinbase upgraded to Buy from Hold at Daiwa
- $236.71 /
+3.445 (+1.48%) - 05/30/23 Roth MKM
- Constellation Brands upgraded to Buy from Neutral at Roth MKM
- 05/08/23 Gordon Haskett
- Barclays 13F shows 'interesting' Constellation Brands buy, says Gordon Haskett
- 04/11/23 Barclays
- Constellation Brands price target lowered to $277 from $279 at Barclays
- 04/10/23 Deutsche Bank
- Constellation Brands price target raised to $218 from $210 at Deutsche Bank
- $334.32 /
+14.66 (+4.59%) - 05/30/23 Roth MKM
- Boston Beer upgraded to Buy from Neutral at Roth MKM
- 04/28/23 Deutsche Bank
- Boston Beer price target raised to $297 from $291 at Deutsche Bank
- 04/28/23 TD Cowen
- Boston Beer price target lowered to $350 from $375 at TD Cowen
- 04/28/23 Morgan Stanley
- Boston Beer price target lowered to $260 from $270 at Morgan Stanley
- 05/30/23 UBS
- Kenvue initiated with a Neutral at UBS
- 05/30/23 RBC Capital
- Kenvue initiated with an Outperform at RBC Capital
- 05/30/23 BofA
- Kenvue initiated with a Buy at BofA
- 05/30/23 Exane BNP Paribas
- Kenvue initiated with a Neutral at Exane BNP Paribas
- 05/30/23 Citi
- Johnson & Johnson resumed with a Buy at Citi
- 05/30/23 JPMorgan
- JPMorgan starts Kenvue with Overweight on 'resilient growth'
- 05/30/23 Goldman Sachs
- Kenvue initiated with a Neutral at Goldman Sachs
- 05/12/23 Citi
- State Street, BNY Mellon hurt most from FDIC proposal, says Citi
- 05/05/23 JPMorgan
- Comerica upgraded to Overweight from Neutral at JPMorgan
- 05/03/23 Wolfe Research
- Comerica downgraded to Peer Perform from Outperform at Wolfe Research
- 04/21/23 RBC Capital
- Comerica price target lowered to $62 from $68 at RBC Capital
- 05/25/23 Jefferies
- Nvidia price target raised to $472 from $300 at Jefferies
- 05/23/23 BofA
- AMD price target raised to $120 from $105 at BofA
- 05/03/23 BofA
- BofA downgrades AMD to Neutral in 'range of headwinds'
- 04/28/23 Truist
- Intel price target raised to $32 from $29 at Truist
UMGNF Universal Music Group - 04/28/23 Barclays
- Universal Music Group price target lowered to EUR 26.25 from EUR 26.60 at Barclays
- 04/27/23 Credit Suisse
- Universal Music Group price target raised to EUR 24.30 at Credit Suisse
- 04/06/23 Exane BNP Paribas
- Universal Music downgraded to Underperform from Outperform at Exane
- 03/08/23 Morgan Stanley
- Universal Music Group price target lowered to EUR 33 from EUR 36 at Morgan Stanley
- 05/30/23 Truist
- Disney price target lowered to $105 from $121 at Truist
- 05/25/23 KeyBanc
- Disney price target lowered to $107 from $120 at KeyBanc
- 05/25/23 Citi
- ESPN+ could add $20 to Disney shares, says Citi
- 05/19/23 Macquarie
- Disney downgraded to Neutral from Outperform at Macquarie
- $121.28 /
+1.185 (+0.99%) - 05/25/23 KeyBanc
- Dish, Amazon deal may be viewed negatively for AT&T, says at KeyBanc
- 05/24/23 DA Davidson
- Symbotic price target raised to $36 from $30 at DA Davidson
- 05/23/23 Mizuho
- Mizuho ups Amazon target, names a top pick for second half on AI
- 05/08/23 Loop Capital
- Amazon.com AWS slowdown transitory, says Loop Capital
- 05/30/23 JPMorgan
- Google AI chip orders accelerating at Broadcom, says JPMorgan
- 05/24/23 BofA
- Google's three pillars 'still upright' despite Bing in ChatGPT, says BofA
- 05/24/23 BofA
- Partnership with Waymo 'positive for Uber on several fronts,' says BofA
- 05/11/23 DA Davidson
- Sonos price target lowered to $24 from $26 at DA Davidson
- 10/17/22 Morgan Stanley
- Sonos price target lowered to $17 from $20 at Morgan Stanley
- 08/11/22 Morgan Stanley
- Sonos price target lowered to $20 from $28 at Morgan Stanley
- 08/11/22 Stifel
- Sonos price target lowered to $20 from $24 at Stifel
- 05/30/23 RBC Capital
- Equitrans Midstream upgraded to Outperform from Sector Perform at RBC Capital
- 04/21/23 Raymond James
- Equitrans Midstream initiated with a Market Perform at Raymond James
- 04/10/23 Barclays
- Equitrans Midstream price target lowered to $6 from $8 at Barclays
- 01/31/23 Goldman Sachs
- Equitrans Midstream double downgraded to Sell at Goldman on MVP delay
IOVA Iovance Biotherapeutics - 05/30/23 Wells Fargo
- Iovance upgraded to Overweight at Wells Fargo after lifileucel BLA accepted
- 05/30/23 Wells Fargo
- Iovance Biotherapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- 05/30/23 Stifel
- Iovance Biotherapeutics price target raised to $24 from $21 at Stifel
- 05/29/23 Barclays
- Iovance news 'important clearing event' for shares, says Barclays
- 05/17/23 Taglich Brothers
- Tingo Group price target raised to $11.75 from $6.25 at Taglich Brothers
- 05/30/23 Morgan Stanley
- Mosaic price target lowered to $40 from $45 at Morgan Stanley
- 05/30/23 Morgan Stanley
- Nutrien price target lowered to $70 from $80 at Morgan Stanley
- 05/30/23 Morgan Stanley
- CF Industries price target lowered to $70 from $75 at Morgan Stanley
- 05/19/23 JPMorgan
- Nutrien price target lowered to $78 from $92 at JPMorgan
- 05/30/23 Piper Sandler
- Hims & Hers price target lowered to $11 from $12 at Piper Sandler
- 05/09/23 SVB Securities
- SVB Securities keeps Market Perform on Hims & Hers, raises price target to $11
- 05/09/23 BofA
- Hims & Hers price target raised to $15 from $13.50 at BofA
- 05/09/23 Piper Sandler
- Hims & Hers price target raised to $12 from $11 at Piper Sandler
- $208.83 /
+15.14 (+7.82%) - 02/08/23 Craig-Hallum
- Skyline Champion price target raised to $78 from $65 at Craig-Hallum
- 02/08/23 RBC Capital
- Skyline Champion price target raised to $65 from $54 at RBC Capital
- 12/30/22 Wedbush
- Wedbush favors four homebuilding stocks heading into 2023
- 12/14/22 Barclays
- Skyline Champion downgraded to Equal Weight from Overweight at Barclays
- 04/26/23 JMP Securities
- CureVac price target lowered to $24 from $34 at JMP Securities
- 01/30/23 JMP Securities
- JMP Securities says older-adult update continues to look encouraging for CureVac
- 01/19/23 UBS
- UBS upgrades CureVac after 'major milestone and clearing event'
- 01/19/23 UBS
- CureVac upgraded to Buy from Neutral at UBS
- 01/03/23 H.C. Wainwright
- H.C. Wainwright adjusts MediWound target to $23 on NexoBrid news, reverse split
- 12/30/22 TD Cowen
- MediWound price target raised to $25 from $6 at Cowen
- 12/29/22 Oppenheimer
- MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer
- 12/22/22 Maxim
- MediWound initiated with a Buy at Maxim
- 11/29/22 Jefferies
- TEN, Ltd. price target raised to $26 from $25 at Jefferies
- 11/23/22 Stifel
- TEN, Ltd. price target raised to $19 from $16 at Stifel
- 09/06/22 Jefferies
- TEN, Ltd. upgraded to Buy from Hold at Jefferies
- 07/20/22 Jefferies
- TEN, Ltd. initiated with a Hold at Jefferies
- $200.11 /
+6.975 (+3.61%) - 04/19/23
- Tesla reports Q1 EPS 85c, consensus 85c
- 04/19/23
- Notable companies reporting after market close
- 03/02/23
- Aehr Test Systems reiterates annual guidance, comments on Tesla statements
- 01/25/23
- Tesla reports Q4 EPS $1.19, consensus $1.13
- 05/30/23
- TEN, Ltd. reports Q1 EPS $5.69 vs. (13c) last year
- 03/16/23
- TEN, Ltd. reports Q4 EPS $3.17 vs. ($5.05) last year
- 05/15/23
- Tingo Group reports Q1 EPS 33c vs 7c last year
- 03/31/23
- Tingo Group reports 2022 EPS (36c) vs. (32c) last year
- $236.71 /
+3.445 (+1.48%) - 04/06/23
- Constellation Brands sees 2024 comparable EPS $11.70-$12.00, consensus $11.68
- 04/06/23
- Constellation Brands reports Q4 comparable EPS ex-Canopy $2.15
- 04/06/23
- Constellation Brands reports Q4 comparable EPS $1.98, consensus $1.82
- 04/05/23
- Notable companies reporting before tomorrow's open
- 05/10/23
- Sonos lowers 2023 revenue outlook to $1.625B-$1.675B from $1.7B-$1.8B
- 05/10/23
- Sonos reports Q2 EPS 4c vs. 26c last year
- 02/08/23
- Sonos affirms FY23 revenue view of $1.7B-$1.8B, consensus $1.73B
- 02/08/23
- Sonos reports Q1 EPS 79c, consensus 40c
- 05/30/23
- Skyline Champion reports Q4 EPS $1.00, consensus 93c
- 02/06/23
- Skyline Champion reports Q3 EPS $1.44, consensus 92c
- $334.32 /
+14.66 (+4.59%) - 04/27/23
- Boston Beer sees FY23 EPS $6.00-$10.00, consensus $7.45
- 04/27/23
- Boston Beer reports Q1 EPS (73c), consensus (31c)
- 02/15/23
- Boston Beer sees FY23 GAAP EPS $6.00-$10.00, consensus $11.02
- 02/15/23
- Boston Beer reports Q4 GAA EPS (93c), consensus 70c
- 04/27/23
- Oshkosh reports Q1 EPS $1.59, consensus $1.02
- 01/31/23
- Oshkosh sees FY23 EPS $5.50, consensus $6.55
- 01/31/23
- Oshkosh reports Q4 EPS $1.60, consensus $1.73
- $411.86 /
+22.51 (+5.78%) - 05/24/23
- Nvidia jumps 15% to $350.53 after Q1 beat, better than expected guidance
- 05/24/23
- Nvidia sees Q2 revenue $11B +/- 2%, consensus 7.15B
- 05/24/23
- Nvidia sees Q2 revenue $11B, +/- 2%, consensus $7.15B
- 05/24/23
- Nvidia reports Q1 EPS $1.09, consensus 92c
- 05/10/23
- Nutrien cuts FY23 EPS view to $5.50-$7.50 from $8.45-$10.65, consensus $8.63
- 05/10/23
- Nutrien reports Q1 EPS $1.11, consensus $1.48
- 02/15/23
- Nutrien sees FY23 adjusted EPS $8.45-$10.65, consensus $11.49
- 02/15/23
- Nutrien reports Q4 adjusted EPS $2.02, consensus $2.62
- 04/18/23
- Netflix sees Q2 EPS $2.84, consensus $3.05
- 04/18/23
- Netflix reports Q1 EPS $2.88, consensus $2.86
- 04/18/23
- Notable companies reporting after market close
- 01/19/23
- Netflix sees Q1 EPS $2.82, consensus $2.97
- 05/03/23
- MagnaChip reports Q1 EPS (24c), consensus (27c)
- 02/16/23
- MagnaChip sees Q1 revenue $55M-$59M ,consensus $63.63M
- 02/16/23
- MagnaChip reports Q4 non-GAAP EPS 36c, consensus (20c)
- 05/30/23
- MediWound reports Q1 EPS (44c), consensus (30c)
- 03/16/23
- MediWound reports Q4 EPS ($1.18), consensus (59c)
- 04/18/23
- Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65
- 04/18/23
- Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51
- 04/17/23
- Notable companies reporting before tomorrow's open
- 02/28/23
- Fate Therapeutics reports Q4 EPS (58c), consensus (86c)
- 04/25/23
- JBT Corporation backs FY23 EPS view $5.00-$5.50, consensus $5.34
- 04/25/23
- JBT Corporation sees Q2 adjusted EPS $1.10-$1.25, consensus $1.24
- 04/25/23
- JBT Corporation reports Q1 adjusted EPS 94c, consensus 73c
- 02/21/23
- JBT Corporation sees FY23 adjusted EPS $5.00-$5.50, consensus $5.46
IOVA Iovance Biotherapeutics - 05/09/23
- Iovance Biotherapeutics reports Q1 EPS (50c), consensus (74c)
- 02/28/23
- Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c)
- 04/27/23
- Intel sees Q2 EPS adjusted (4c), consensus 1c
- 04/27/23
- Intel reports Q1 adjusted EPS (4c), consensus (15c)
- 04/27/23
- Notable companies reporting after market close
- 02/22/23
- Intel backs Q1 EPS view (15c), consensus (15c)
- 05/08/23
- Hims & Hers sees Q2 revenue $200M-$205M, consensus $183.3M
- 05/08/23
- Hims & Hers raises FY23 revenue view to $810M-$830M, consensus $755.28M
- 05/08/23
- Hims & Hers reports Q1 EPS (5c), consensus (7c)
- 02/27/23
- Hims & Hers sees FY23 revenue $735M-$755M, consensus $726.92M
- 04/25/23
- Alphabet reports Q1 EPS $1.17, consensus $1.07
- 04/25/23
- Alphabet reports Q1 Google Cloud revenue $7.45B vs. $5.82B last year
- 04/25/23
- Alphabet reports Q1 EPS $1.17, consensus $1.07
- 04/25/23
- Notable companies reporting after market close
- 05/22/23
- Ford backs FY23 adjusted EBIT view of $9B-$11B
- 05/02/23
- Ford reports Q1 adjusted EPS 63c, consensus 41c
- 05/02/23
- Notable companies reporting after market close
- 05/01/23
- Notable companies reporting before tomorrow's open
- 05/02/23
- Equitrans Midstream reports Q1 adjusted EPS 22c, consensus 15c
- 02/21/23
- Equitrans Midstream sees FY23 adjusted EBITDA $1.06B-$1.14B
- 02/21/23
- Equitrans Midstream sees Q1 adjusted EBITDA $270M-$290M
- 02/21/23
- Equitrans Midstream sees Q1 adjusted EBITDA $270M-$290M
- $208.83 /
+15.14 (+7.82%) - 05/30/23
- Elbit Systems reports Q1 EPS $1.70 vs. $1.22 last year
- 03/28/23
- Elbit Systems reports Q4 adjusted EPS $1.68 vs. $2.14 last year
- 05/10/23
- Disney reports Q2 EPS ex-items 93c, consensus 93c
- 05/10/23
- Notable companies reporting after market close
- 02/08/23
- Disney reports Q1 EPS ex-items 99c, consensus 78c
- 02/08/23
- Notable companies reporting after market close
- 05/30/23
- CureVac reports Q1 revenue EUR 7.1M vs. EUR 24.4M last year
- 04/25/23
- CureVac reports Q4 revenue EUR 11.7M vs. EUR 41.2M last year
- 05/04/23
- Coinbase reports Q1 subscription and services revenue $362M
- 05/04/23
- Coinbase maintains goal to improve FY23 EBITDA versus FY22
- 05/04/23
- Coinbase reports Q1 EPS (34c) vs ($1.98) last year
- 02/21/23
- Coinbase reports Q4 EPS ($2.46) vs. $3.32 y/y
- 04/20/23
- Comerica reports Q1 EPS $2.39, consensus $2.29
- 04/19/23
- Notable companies reporting before tomorrow's open
- 01/19/23
- Comerica reports Q4 EPS $2.58, consensus $2.55
- 03/03/23
- ChargePoint sees Q1 revenue $122M-$132M, consensus $152.5M
- 03/02/23
- ChargePoint reports Q4 EPS (23c), consensus (17c)
- 12/01/22
- ChargePoint narrows FY23 revenue view to $475M-$485M from $450M-$500M
- 12/01/22
- ChargePoint sees Q4 revenue $160M-$170M, consensus $160.91M
- $121.28 /
+1.185 (+0.99%) - 04/27/23
- Amazon sees Q2 revenue $127B-$133B, consensus $129.83B
- 04/27/23
- Amazon reports Q1 EPS 31c with Rivian loss, consensus 21c
- 02/02/23
- Amazon sees Q1 revenue $121B-$126B, consensus $125.11B
- 05/21/23
- Fly Intel: Top five weekend stock stories
- 05/04/23
- Apple sees Q3 revenue growth 'similar' to Q2, consensus $84.71B
- 05/04/23
- Apple sees Q3 revenue 'similar' to Q2, consensus $84.71B
- 05/04/23
- Apple reports Q2 EPS $1.52, consensus $1.43
|
|
Upgrade
| ShowHide Related Items >><< IOVA Iovance Biotherapeutics - 05/26/23
- Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel
- 03/24/23
- Iovance Biotherapeutics completes BLA submission for lifileucel
- 03/10/23
- Iovance says it does not hold deposits, securities at Silicon Valley Bank
- 01/23/23
- Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M
IOVA Iovance Biotherapeutics - 05/30/23 Wells Fargo
- Iovance Biotherapeutics upgraded to Overweight from Equal Weight at Wells Fargo
- 05/30/23 Stifel
- Iovance Biotherapeutics price target raised to $24 from $21 at Stifel
- 05/29/23 Barclays
- Iovance news 'important clearing event' for shares, says Barclays
- 05/23/23 Baird
- Iovance Biotherapeutics price target raised to $23 from $20 at Baird
IOVA Iovance Biotherapeutics - 05/09/23
- Iovance Biotherapeutics reports Q1 EPS (50c), consensus (74c)
- 02/28/23
- Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c)
IOVA Iovance Biotherapeutics - 05/19/23
- Biotech Alert: Searches spiking for these stocks today
- 04/13/23
- Biotech Alert: Searches spiking for these stocks today
- 03/30/23
- Biotech Alert: Searches spiking for these stocks today
- 03/27/23
- What You Missed On Wall Street On Monday
|
|
Upgrade
|
Wells Fargo analyst Yanan… ShowHide Related Items >><< IOVA Iovance Biotherapeutics - 05/26/23
- Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel
- 03/24/23
- Iovance Biotherapeutics completes BLA submission for lifileucel
- 03/10/23
- Iovance says it does not hold deposits, securities at Silicon Valley Bank
- 01/23/23
- Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M
IOVA Iovance Biotherapeutics - 05/30/23 Stifel
- Iovance Biotherapeutics price target raised to $24 from $21 at Stifel
- 05/29/23 Barclays
- Iovance news 'important clearing event' for shares, says Barclays
- 05/23/23 Baird
- Iovance Biotherapeutics price target raised to $23 from $20 at Baird
- 05/10/23 Baird
- Iovance Biotherapeutics price target lowered to $20 from $25 at Baird
IOVA Iovance Biotherapeutics - 05/09/23
- Iovance Biotherapeutics reports Q1 EPS (50c), consensus (74c)
- 02/28/23
- Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c)
IOVA Iovance Biotherapeutics - 05/19/23
- Biotech Alert: Searches spiking for these stocks today
- 04/13/23
- Biotech Alert: Searches spiking for these stocks today
- 03/30/23
- Biotech Alert: Searches spiking for these stocks today
- 03/27/23
- What You Missed On Wall Street On Monday
|
|
Recommendations
| ShowHide Related Items >><< IOVA Iovance Biotherapeutics - 05/26/23
- Iovance Biotherapeutics announces FDA acceptance of BLA of Lifileucel
- 03/24/23
- Iovance Biotherapeutics completes BLA submission for lifileucel
- 03/10/23
- Iovance says it does not hold deposits, securities at Silicon Valley Bank
- 01/23/23
- Clinigen divests Proleukin to Iovance Biotherapeutics for GBP 166.7M
IOVA Iovance Biotherapeutics - 05/29/23 Barclays
- Iovance news 'important clearing event' for shares, says Barclays
- 05/23/23 Baird
- Iovance Biotherapeutics price target raised to $23 from $20 at Baird
- 05/10/23 Baird
- Iovance Biotherapeutics price target lowered to $20 from $25 at Baird
- 03/27/23 Stifel
- Stifel leans positive on approval of Iovance's BLA submission for lifileucel
IOVA Iovance Biotherapeutics - 05/09/23
- Iovance Biotherapeutics reports Q1 EPS (50c), consensus (74c)
- 02/28/23
- Iovance Biotherapeutics reports Q4 EPS (64c), consensus (64c)
IOVA Iovance Biotherapeutics - 05/19/23
- Biotech Alert: Searches spiking for these stocks today
- 04/13/23
- Biotech Alert: Searches spiking for these stocks today
- 03/30/23
- Biotech Alert: Searches spiking for these stocks today
- 03/27/23
- What You Missed On Wall Street On Monday
|
